Download as PDF, PPTX
![https://www.ncbi.nlm.nih.gov/pubmed/8603777
More than 20 years ago…
Zymogenetics Corporation is a wholly owned subsidiary of Novo
Nordisk A/S, a manufacturer of therapeutics for the treatment of
diabetes.
BBB, blood-brain barrier; CRH, corticotropin-releasing hormone;
MES, 2-[Nmorpholino]ethanesulfonic acid; NPY, neuropeptide Y;
PVN, paraventricular nucleus.
DIABETES, VOL. 45, APRIL 1996
(A) Serum glucose in ob/ob and db/db mice after 5 daily intraperitoneal
injections of 150 µg of recombinant murine leptin or saline
genotype: ob/ob db/db
treatment:
Specificity of Leptin Action on
Elevated Blood Glucose Levels and
Hypothalamic Neuropeptide Y Gene
Expression in ob/ob Mice
Michael W. Schwartz, Denis G. Baskin, Thomas R. Bukowski,
Joseph L. Kuijper, Donald Foster, Gerry Lasser, Donna E.
Prunkard, Daniel Porte, Jr., Stephen C. Woods, Randy J. Seeley,
and David S. Weigle](https://image.slidesharecdn.com/dsiglucose-2018masterslidesharefinal-180712135928/75/From-Mouse-to-Monkey-Revolutionizing-Research-via-Preclinical-Continuous-Glucose-Telemetry-15-2048.jpg)
![© 2018 Data Sciences International
• Isolate left carotid artery
• Ligate at bifurcation
• Two additional sutures for
hemostasis
Mouse Glucose Surgery
[superior - cranial]
[inferior - caudal]](https://image.slidesharecdn.com/dsiglucose-2018masterslidesharefinal-180712135928/75/From-Mouse-to-Monkey-Revolutionizing-Research-via-Preclinical-Continuous-Glucose-Telemetry-40-2048.jpg)
Uploaded byInsideScientific
From Mouse to Monkey: Revolutionizing Research via Preclinical Continuous Glucose Telemetry
The document discusses a wireless glucose monitoring methodology utilized by researchers to revolutionize preclinical research, particularly in studying obesity, diabetes, and cardiovascular diseases. It summarizes findings from continuous glucose telemetry in animal models, including experiments on high-fat diet effects and drug therapy efficacy. The use of advanced monitoring techniques over the past nine years has significantly enhanced the understanding of metabolic responses and hormone actions in these disease processes.
More Related Content
Similar to From Mouse to Monkey: Revolutionizing Research via Preclinical Continuous Glucose Telemetry
From Mouse to Monkey: Revolutionizing Research via Preclinical Continuous Glucose Telemetry
- 1. From Mouse toMonkey: Revolutionizing Research via Preclinical Continuous Glucose Telemetry Scientists present wireless glucose monitoring methodology, best practices, research findings, and discuss the power of continuous glucose profiles, particularly when combined with other gold standard assays to study obesity, diabetes and cardiovascular related diseases.
- 2. From Mouse toMonkey: Revolutionizing Research via Preclinical Continuous Glucose Telemetry Dr. Stephanie Simonds NHMRC/NHF Research fellow Monash University, Melbourne, Australia Megan Fine, DVM MS, DACVS-LA Veterinary Surgeon, Attending Veterinarian Data Sciences International
- 3. InsideScientific is anonline educational environment designed for life science researchers. Our goal is to aid in the sharing and distribution of scientific information regarding innovative technologies, protocols, research tools and laboratory services
- 4. To access webinarcontent, Q&A reports, FAQ documents, and information on lab workshops, subscribe to our mail list
- 5. Copyright 2018 S.Simonds and InsideScientific. All Rights Reserved. Experimental applications of DSI continuous blood glucose monitoring in mice. Dr. Stephanie Simonds NHMRC/NHF Research fellow Monash University, Melbourne, Australia
- 6. We have usedDSI equipment for >9 years We use this equipment for the study of chronic diseases including diabetes and cardiovascular diseases HD-X11 HD-XG PA-C10
- 7.
- 8. Lean DIO 0 10 20 30 40 50 60 70 Bodyweight(grams) *** High FatDiet-fed Mouse Model Of Obesity
- 9. Using Continuous Glucose Monitoringto Assess Phenotypes
- 10. Lean DIO 0 10 20 30 40 50 60 70 Bodyweight(grams) *** Continuous TelemetricBlood Glucose 7:00:009:00:0011:00:0013:00:0015:00:0017:00:0019:00:0021:00:0023:00:001:00:003:00:005:00:00 2 4 6 8 10 Time (Hrs:Min:Sec) Bloodglucose(mmol/l) DIO fed Lean fed Light Phase Dark Phase 7:00:009:00:0011:00:0013:00:0015:00:0017:00:0019:00:0021:00:0023:00:001:00:003:00:005:00:00 2 Time (Hrs:Min:Sec) Blo DIO fed Lean fed
- 11. 0:00:004:00:008:00:00 12:00:00 16:00:00 20:00:000:00:004:00:008:00:00 12:00:00 16:00:00 20:00:000:00:004:00:008:00:00 12:00:00 16:00:00 20:00:000:00:004:00:008:00:00 32 34 36 38 Temp(Degrees) temp when changedto HFD Switch to HFD 0:00:004:00:008:00:00 12:00:00 16:00:00 20:00:000:00:004:00:008:00:00 12:00:00 16:00:00 20:00:000:00:004:00:008:00:00 12:00:00 16:00:00 20:00:000:00:004:00:008:00:00 0 50 100 150 Activity (Arbitraryunit) activity when changed to HFD 0:00:004:00:008:00:00 12:00:00 16:00:00 20:00:000:00:004:00:008:00:00 12:00:00 16:00:00 20:00:000:00:004:00:008:00:00 12:00:00 16:00:00 20:00:000:00:004:00:008:00:00 0 2 4 6 8 10 12 14 Blood glucose(mmol/l) BG when changed to HFD 00:00:008:00:00 12:00:00 16:00:00 20:00:000:00:004:00:008:00:00 12:00:00 16:00:00 20:00:000:00:004:00:008:00:00 12:00:00 16:00:00 20:00:000:00:004:00:008:00:00 Switch to HFD Initial Physiological Changes When Mice are Switched to a HFD
- 12. Using Continuous GlucoseMonitoring to Assess Drug Therapy Efficacy
- 13. 0:00:00 0:30:00 1:00:00 1:30:00 2:00:00 2:30:00 3:00:00 3:30:00 4:00:00 4:30:00 5:00:00 5:30:00 6:00:00 6:30:00 7:00:00 0 10 20 30 40 Time (Hrs:Min: Sec) Blood glucose(mmol/l) Drugtreatment Glucose Bolus Veh -60 0 30 0 5 10 15 20 25 Time (Mins) Blood glucose(mmol/l) Manual gluose Veh Synthetic compound ‘B’ Synthetic compound ‘A’ Native Peptide ‘A’ Combination Drug ‘A’ + ‘B’ -60 0 30 0 5 10 15 20 25 Time (Mins) Blood glucose(mmol/l) Manual gluose Veh Synthetic compound ‘B’ Synthetic compound ‘C’ Synthetic compound ‘A’ Native Peptide ‘A’ Synthetic compound ‘D’ Combination Drug ‘A’ + ‘B’ Manual vs. Continuous Monitoring 0 30 Time (Mins) anual gluose Veh Synthetic compound ‘B’ Synthetic compound ‘C’ Synthetic compound ‘A’ Native Peptide ‘A’ Synthetic compound ‘D’ Combination Drug ‘A’ + ‘B’ Manual Continuous 0:00:00 0:30:00 1:00:00 1:30:00 2:00:00 2:30:00 3:00:00 3:30:00 4:00:00 4:30:00 5:00:00 5:30:00 6:00:00 6:30:00 7 0 Time (Hrs:Min: Sec) Synthetic compound ‘C’ Synthetic compound ‘A’ Native Peptide ‘A’ Synthetic compound ‘D’ Synthetic compound ‘E’ Combination Drug ‘A’ + ‘B’ Synthetic compound ‘B’ Veh 0:00:00 0:30:00 1:00:00 1:30:00 2:00:00 2:30:00 3:00:00 3:30:00 4:00 Time (Hrs:Min: Synthetic compound ‘C’ Synthetic compound ‘A’ Native Peptide ‘A’ Synthetic compound ‘D’ Synthetic compound ‘E’ Combination Drug ‘A’ + ‘B’ Synthetic compound ‘B’ Veh Veh Compound ‘F’ Compound ‘A’ Compound ‘B’ Compound ‘A’ + ‘B’ Compound ‘C’ Compound ‘D’ Veh Compound ‘F’ Compound ‘A’ Compound ‘B’ Compound ‘A’ + ‘B’ Compound ‘C’ Compound ‘D’ Compound ‘E’
- 14. Using Continuous GlucoseMonitoring to Determine Hormone Physiological Actions
- 15. https://www.ncbi.nlm.nih.gov/pubmed/8603777 More than 20years ago… Zymogenetics Corporation is a wholly owned subsidiary of Novo Nordisk A/S, a manufacturer of therapeutics for the treatment of diabetes. BBB, blood-brain barrier; CRH, corticotropin-releasing hormone; MES, 2-[Nmorpholino]ethanesulfonic acid; NPY, neuropeptide Y; PVN, paraventricular nucleus. DIABETES, VOL. 45, APRIL 1996 (A) Serum glucose in ob/ob and db/db mice after 5 daily intraperitoneal injections of 150 µg of recombinant murine leptin or saline genotype: ob/ob db/db treatment: Specificity of Leptin Action on Elevated Blood Glucose Levels and Hypothalamic Neuropeptide Y Gene Expression in ob/ob Mice Michael W. Schwartz, Denis G. Baskin, Thomas R. Bukowski, Joseph L. Kuijper, Donald Foster, Gerry Lasser, Donna E. Prunkard, Daniel Porte, Jr., Stephen C. Woods, Randy J. Seeley, and David S. Weigle
- 16.
- 17. Using Continuous GlucoseMonitoring in Combination with Chemogenetics
- 18. • X-Cre mice •Injected into the DMH with chemogenic activator virus • Mice allowed to recover • DSI equipment utilized in monitoring of blood glucose, core body temperature and activity Study Overview
- 19. 0:10:000:30:000:50:001:10:001:30:001:50:002:10:002:30:002:50:003:10:003:30:00 0 2 4 6 8 10 Time (Hrs:Min: Sec) Blood glucose(mmol/l) DMHlepR activation DMH lepR no activation * ** ** **** ** **** Either activation or no activation 0:10:000:30:000:50:001:10:001:30:001:50:002:10:002:30:002:50:003:10:003:30:00 30 32 34 36 38 Time (Hrs:Min: Sec) Coretemp(Degrees) DMH lepR activation DMH lepR no activation * *** ** Either activation or no activation 0:10:000:30:000:50:001:10:001:30:001:50:002:10:002:30:002:50:003:10:003:30:00 0 5 10 15 Time (Hrs:Min: Sec) Activity (Arbitraryunit) DMH lepR activation DMH lepR no activation * Either activation or no activation DMH receptor activation DMH veh non- activation DMH receptor activation DMH veh non- activation DMH receptor activation DMH veh non- activation Activation vs. Non Activation of X Receptor Expressing Neurons Within The Dorsomedial Hypothalamic Nucleus
- 20. • X-Cre mice •Injected into the DMH with chemogenic activator virus • Mice allowed to recover • DSI equipment utilized in monitoring of blood glucose, core body temperature and activity in response to chemogenic neuron activation of receptors and in response to blood glucose bolus Study Overview
- 21. 00:10:000:20:000:30:000:40:000:50:001:00:001:10:001:20:001:30:001:40:001:50:002:00:002:10:002:20:002:30:002:40:002:50:003:00:003:10:003:20:00 0 5 10 15 Activity (Arbitraryunit) DMH lepR activation+ glucose *** *** *** ** DMH lepR no activation + glucose *** Activation or no activation All mice Glucose bolus 00:10:000:20:000:30:000:40:000:50:001:00:001:10:001:20:001:30:001:40:001:50:002:00:002:10:002:20:002:30:002:40:002:50:003:00:003:10:003:20:00 0 10 20 30 Blood glucose(mmol/l) DMH lepR activation + glucose *** *** ** * ** ** ** ** ** ** ** DMH lepR no activation + glucose Activation or no activation All mice Glucose bolus 00:10:000:20:000:30:000:40:000:50:001:00:001:10:001:20:001:30:001:40:001:50:002:00:002:10:002:20:002:30:002:40:002:50:003:00:003:10:003:20:00 30 32 34 36 38 Time (Hrs:Min: Sec) Coretemp(Degrees) DMH lepR activation + glucose DMH lepR no activation + glucose Activation or no activation All mice Glucose bolus DMH receptor activation + glucose DMH veh non- activation + glucose DMH receptor activation + glucose DMH veh non- activation + glucose DMH receptor activation + glucose DMH veh non- activation + glucose Physiological Effects of Glucose Bolus and Activation vs. Non Activation of X-cre Expressing Neurons Within The Dorsomedial Hypothalamic Nucleus
- 22. Using Continuous GlucoseMonitoring in Combination With Central AAV Cre Neuronal Knockdown Modulating central physiology & measuring peripheral outputs
- 23. baseline 15 30 45 60 90 1200 10 20 30 40 Blood glucose(mmol/l) Time (Mins) Baseline Week 1 Week3 ** **** X lox/lox mice 0:00:000:15:000:30:000:45:001:00:001:15:001:30:001:45:002:00:002:15:002:30:002:45:00 0 10 20 30 40 Time (Hrs:Min: Sec) Blood glucose(mmol/l) DMH AAV Cre in LepR flox mice day 17 DMH AAV Cre in LepR flox mice day 4 Deletion of X-receptor in DMH Impairs Glucose Tolerance DMH AAV Cre in x Cre receptor mice day 17 DMH AAV Cre in x Cre receptor mice day 4 0:00:000:15:000:30:000:45:001:00:001:15:001:30:001:45:002:00:002:15:002:30:002:45:00 0 10 20 30 40 Time (Hrs:Min: Sec) Blood glucose(mmol/l) DMH AAV Cre in LepR flox mice day 17 DMH AAV Cre in LepR flox mice day 4
- 24. 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 -10 -5 0 5 10 Changeinbloodglucose(mmol/l) change DMH AAV Crein LepR flox mice DMH AAV Scrambled in LepR flox mice Day 7 Day 14 Day 18 Central AAV-Cre Receptor Deletion Increases Blood Glucose X lox/lox mice DMH AAV Cre in x Cre receptor mice DMH AAV Scrambled in x Cre receptor mice 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 19:00:00 7:00:00 -10 -5 0 5 10 Changeinbloodglucose(mmol/l) change DMH AAV Cre in LepR flox mice DMH AAV Scrambled in LepR flox mice Day 7 Day 14 Day 18
- 25. 19:00:00 23:00:00 3:00:00 7:00:00 11:00:00 15:00:00 -2 0 2 4 6 8 10 Time (Hrs:Min: Sec) Changeinbloodglucose(mmol/l) ChangeDAY 7 DMH AAV Cre in LepR flox mice DMH AAV Scrambled in LepR flox mice 19:00:00 23:00:00 3:00:00 7:00:00 11:00:00 15:00:00 -2 0 2 4 6 8 10 Time (Hrs:Min: Sec) Changeinbloodglucose(mmol/l) Change DAY 14 DMH AAV Cre in LepR flox mice DMH AAV Scrambled in LepR flox mice 19:00:00 23:00:00 3:00:00 7:00:00 11:00:00 15:00:00 -5 0 5 10 15 Time (Hrs:Min: Sec) Changeinbloodglucose(mmol/l) Change DAY 18 DMH AAV Cre in LepR flox mice DMH AAV Scrambled in LepR flox mice Time (Hrs:Min:Sec) x lox/lox mice Deletion of X-Receptors Centrally Increases Blood Glucose DMH AAV Cre in x Cre receptor mice DMH AAV Scrambled in x Cre receptor mice 19:00:00 23:00:00 3:00:00 7:00:00 11:00:00 15:00:00 -2 0 Time (Hrs:Min: Sec) Chang DMH AAV Cre in LepR flox mice DMH AAV Scrambled in LepR flox mice Time (Hrs:Min:Sec) Time (Hrs:Min:Sec) Change DAY 18Change DAY 14Change DAY 7
- 26. Monash University Prof. MichaelCowley Dr. Jack Pryor Acknowledgements
- 27. Glucose Telemetry Surgery Copyright2018 Data Sciences International (DSI) and InsideScientific. All Rights Reserved. Megan Fine, DVM MS, DACVS-LA Veterinary Surgeon, Attending Veterinarian DSI
- 28. © 2018 DataSciences International Overview • Why blood glucose? • Glucose telemetry surgery in mouse, rat and large animals • Calibration best practices • Combining additional endpoints • Questions
- 29. © 2018 DataSciences International Why blood glucose?
- 30. © 2018 DataSciences International Why blood glucose? • Decreased handling • Minimize stress • Continuous data • Reduced variability • ↑ Statistical power • Effort to ↓ animal numbers accessiblebiosci.blogspot.com
- 31. © 2018 DataSciences International Glucose Telemetry Surgery • Arterial insertion – Sensor tip in freely flowing blood • Temperature from device body • Sensor hydration • Surgical recovery • Calibration
- 32. © 2018 DataSciences International Glucose Telemetry Surgery HD-XG Size Implant Body = ~20mm Catheter = ~65mm Total = ~85mm
- 33. © 2018 DataSciences International Mouse Glucose Surgery • Pre-operative planning – Ensure complete circle of Willis • Ligate and recover Click here to learn more about HD-XG glucose telemetry
- 34. © 2018 DataSciences International • Pre-operative planning – Ensure complete circle of Willis • Ligate and recover – Insertion depth assessment • Ligate and measure Bifurcation Junction Mouse Glucose Surgery
- 35. © 2018 DataSciences International • Pre-operative planning – Ensure complete circle of Willis • Ligate and recover – Insertion depth assessment • Ligate and measure • Example; 10 mm bifurcation → junction 10 mm Mouse Glucose Surgery
- 36. © 2018 DataSciences International • Pre-operative planning – Ensure complete circle of Willis • Ligate and recover – Insertion depth assessment • Ligate and measure • Example; 10 mm bifurcation → junction – Determine insertion depths • Example 12 mm insertion 12 mm Mouse Glucose Surgery
- 37. © 2018 DataSciences International • Pre-operative planning – Ensure complete circle of Willis • Ligate and recover – Insertion depth assessment • Ligate and measure – Determine insertion depths • Varies by weight, sex & strain Animal # Weight (g) Measured depth (mm) add 2 mm 1 28.7 11 8 30.3 10 12 9 30.6 12 15 31.4 12.5 21 32.4 13 22 32.4 11 13 29 34.6 14 Mouse Glucose Surgery Animal # Weight (g) 1 28.7 2 28.8 3 28.9 4 28.9 5 29.4 6 29.5 7 29.8 8 30.3 9 30.6 10 31.1 11 31.3 12 31.3 13 31.4 14 31.4 15 31.4 16 31.6 17 31.8 18 32.1 19 32.1 20 32.2 21 32.4 22 32.4 23 32.5 24 32.6 25 32.7 26 32.9 27 33 28 33.5 29 34.6 30 34.7
- 38. © 2018 DataSciences International Intraperitoneal Placement • Minimum weight 23 g • Core body temperature • Major surgery Subcutaneous Placement • Minimum weight 19 g • Temperature trends • Care with pocket size Mouse Glucose Surgery
- 39. © 2018 DataSciences International • Isolate left carotid artery • Isolate left carotid artery Mouse Glucose Surgery http://erovideo.us/d1aebe/mouse-vessel-anatomy Click here to learn more about DSI surgical services
- 40. © 2018 DataSciences International • Isolate left carotid artery • Ligate at bifurcation • Two additional sutures for hemostasis Mouse Glucose Surgery [superior - cranial] [inferior - caudal]
- 41. © 2018 DataSciences International • Isolate left carotid artery • Ligate at bifurcation • Two additional sutures for hemostasis • Prep needle for puncture Mouse Glucose Surgery
- 42. © 2018 DataSciences International • Measure sensor: White marker → tip 12 ± 0.5 mm Mouse Glucose Surgery
- 43. © 2018 DataSciences International • Grasp sensor – Vessel cannulation forceps – On edge – Behind exposed wells Mouse Glucose Surgery
- 44. © 2018 DataSciences International • Grasp sensor – Vessel cannulation forceps – On edge – Behind exposed wells • Puncture and insert – Remember depth Mouse Glucose Surgery
- 45. © 2018 DataSciences International • Grasp sensor – Vessel cannulation forceps – On edge – Behind exposed wells • Puncture and insert – Remember depth • Secure with three sutures • Flat under skin Mouse Glucose Surgery
- 46. © 2018 DataSciences International Intraperitoneal Placement • Prior to cannulation • Midline laparotomy Subcutaneous Placement • Tunnel after cannulation • Right lateral flank Mouse Glucose Surgery
- 47. © 2018 DataSciences International Rat Glucose Surgery
- 48. © 2018 DataSciences International Rat Glucose Surgery • Intraperitoneal placement Rat Glucose Surgery
- 49. © 2018 DataSciences International Rat Glucose Surgery • Intraperitoneal placement • Occlusion sutures – Distal to renal vein – Proximal to iliac bifurcation Rat Glucose Surgery
- 50. © 2018 DataSciences International Rat Glucose Surgery • Intraperitoneal placement • Occlusion sutures • Insert sensor Rat Glucose Surgery
- 51. © 2018 DataSciences International Rat Glucose Surgery • Intraperitoneal placement • Occlusion sutures • Insert sensor • Seal with Vetbond Rat Glucose Surgery
- 52. © 2018 DataSciences International Rat Glucose Surgery • Intraperitoneal placement • Occlusion sutures • Insert sensor • Seal with Vetbond • Secure with fiber patches Rat Glucose Surgery
- 53. © 2018 DataSciences International Rat Glucose Surgery • Intraperitoneal placement • Occlusion sutures • Seal with Vetbond • Secure with fiber patches • Tack connector Rat Glucose Surgery
- 54. © 2018 DataSciences International Rat Glucose Surgery • Intraperitoneal placement • Occlusion sutures • Seal with Vetbond • Secure with fiber patches • Tack connector Rat Glucose Surgery
- 55. © 2018 DataSciences International Rat Glucose Surgery • Intraperitoneal placement • Occlusion sutures • Seal with Vetbond • Secure with fiber patches • Tack connector • Secure reference electrode Rat Glucose Surgery
- 56. © 2018 DataSciences International Large Animal Glucose Surgery
- 57. © 2018 DataSciences International • Implant placement Large Animal Glucose Surgery
- 58. © 2018 DataSciences International • Implant placement • Vessel selection Large Animal Glucose Surgery Click here to learn more about large animal glucose telemetry
- 59. © 2018 DataSciences International • Implant placement • Vessel selection • Secure sensor – Miller’s and finger trap Large Animal Glucose Surgery
- 60. © 2018 DataSciences International Calibration Best Practices View calibration tech-note
- 61. © 2018 DataSciences International Calibration Best Practices – Timing!
- 62. © 2018 DataSciences International • Mouse → Saphenous vein https://norecopa.no/films-and-slide-shows/mouse Calibration Best Practices
- 63. © 2018 DataSciences International • Rat → Tail tip puncture Calibration Best Practices
- 64. © 2018 DataSciences International • Mouse – Saphenous vein • Rat – Tail tip puncture • Large animal – May require anesthesia or vascular access ports http://www.norfolkaccess.com Calibration Best Practices
- 65. © 2018 DataSciences International Combining Additional Endpoints • Rat – Glucose and cardiovascular – HD-S11 & XG
- 66. © 2018 DataSciences International • Large animal – Glucose and cardiovascular – M1G Combining Additional Endpoints • Rat – Glucose and cardiovascular – HD-S11 & XG
- 67. Dr. Stephanie Simonds NHMRC/NHFResearch fellow Monash University, Melbourne, Australia Megan Fine, DVM MS, DACVS-LA Veterinary Surgeon, Attending Veterinarian Data Sciences International #LifeScienceWebinar #ISCxDSI Thank You For additional information on the products and applications presented during this webinar please visit www.datasci.com